Background/Aims: The pathophysiology of acute kidney injury (AKI) in ST-elevation myocardial infarction (STEMI) patients remains poorly explored. The involvement of the nitric oxide (NO) pathway has been demonstrated in experimental ischemic AKI. The aim of this study was to assess the predictive value of circulating biomarkers of the NO pathway for AKI in STEMI patients. Methods: Four hundred and twenty-seven STEMI patients treated with primary percutaneous coronary intervention were included. The primary end point was AKI. Biomarkers of the NO pathway (plasma superoxide dismutase [SOD], uric acid, nitrite/nitrate [NOx], neopterin) as well as cardiac biomarkers (B-type natriuretic peptide [BNP] and troponin) were sampled 12 h after admission. The predictive value of circulating biomarkers was evaluated in addition to the multivariate clinical model. Results: AKI developed in 8.9% of patients. The 3-month mortality was significantly higher in patients with AKI (34.2 vs. 4.1%; p < 0.001). SOD, uric acid, NOx, neopterin, BNP and troponin were significantly associated with the development of AKI (area under curve [AUC]-receiver operating curve [ROC] ranging between 0.70 and 0.81). In multivariate analysis cardiogenic shock, neopterin, NOx and troponin were independent predictors of AKI. AUC-ROC of the association of multibiomarkers and clinical model was 0.90 and outperformed the predictive value of the clinical model alone. OR of NOx ≥45 µmol/L was 8.0 (95% CI 3.1–20.6) for AKI. Conclusion: Biomarkers of the NO pathway are associated with the development of AKI in STEMI patients. These results provide insights into the pathophysiology of AKI and may serve at developing preventing strategies for AKI targeting this pathway.

1.
Kanic
V
,
Kompara
G
,
Suran
D
,
Ekart
R
,
Bevc
S
,
Hojs
R
.
Impact of KDIGO-Defined Acute Kidney Injury on Mortality after Percutaneous Coronary Intervention for Acute Myocardial Infarction
.
Cardiorenal Med
.
2018
;
8
(
4
):
332
9
.
[PubMed]
1664-3828
2.
Roberts
JK
,
McCullough
PA
.
The management of acute coronary syndromes in patients with chronic kidney disease
.
Adv Chronic Kidney Dis
.
2014
Nov
;
21
(
6
):
472
9
.
[PubMed]
1548-5595
3.
Rangaswami
J
,
Bhalla
V
,
Blair
JE
,
Chang
TI
,
Costa
S
,
Lentine
KL
, et al;
American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology
.
Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association
.
Circulation
.
2019
Apr
;
139
(
16
):
e840
78
.
[PubMed]
0009-7322
4.
Bruetto
RG
,
Rodrigues
FB
,
Torres
US
,
Otaviano
AP
,
Zanetta
DM
,
Burdmann
EA
.
Renal function at hospital admission and mortality due to acute kidney injury after myocardial infarction
.
PLoS One
.
2012
;
7
(
4
):
e35496
.
[PubMed]
1932-6203
5.
Amin
AP
,
Salisbury
AC
,
McCullough
PA
,
Gosch
K
,
Spertus
JA
,
Venkitachalam
L
, et al
Trends in the incidence of acute kidney injury in patients hospitalized with acute myocardial infarction
.
Arch Intern Med
.
2012
Feb
;
172
(
3
):
246
53
.
[PubMed]
0003-9926
6.
Legrand
M
,
Kandil
A
,
Payen
D
,
Ince
C
.
Effects of sepiapterin infusion on renal oxygenation and early acute renal injury after suprarenal aortic clamping in rats
.
J Cardiovasc Pharmacol
.
2011
Aug
;
58
(
2
):
192
8
.
[PubMed]
0160-2446
7.
Le Dorze
M
,
Legrand
M
,
Payen
D
,
Ince
C
.
The role of the microcirculation in acute kidney injury
.
Curr Opin Crit Care
.
2009
Dec
;
15
(
6
):
503
8
.
[PubMed]
1070-5295
8.
Legrand
M
,
Mik
EG
,
Johannes
T
,
Payen
D
,
Ince
C
.
Renal hypoxia and dysoxia after reperfusion of the ischemic kidney
.
Mol Med
.
2008
Jul-Aug
;
14
(
7-8
):
502
16
.
[PubMed]
1076-1551
9.
Ronco
C
,
Cicoira
M
,
McCullough
PA
.
Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure
.
J Am Coll Cardiol
.
2012
Sep
;
60
(
12
):
1031
42
.
[PubMed]
0735-1097
10.
Legrand
M
,
De Berardinis
B
,
Gaggin
HK
,
Magrini
L
,
Belcher
A
,
Zancla
B
, et al;
Global Research on Acute Conditions Team (GREAT)
.
Evidence of uncoupling between renal dysfunction and injury in cardiorenal syndrome: insights from the BIONICS study
.
PLoS One
.
2014
Nov
;
9
(
11
):
e112313
.
[PubMed]
1932-6203
11.
Tung
YC
,
Chang
CH
,
Chen
YC
,
Chu
PH
.
Combined biomarker analysis for risk of acute kidney injury in patients with ST-segment elevation myocardial infarction
.
PLoS One
.
2015
Apr
;
10
(
4
):
e0125282
.
[PubMed]
1932-6203
12.
Narala
KR
,
Hassan
S
,
LaLonde
TA
,
McCullough
PA
.
Management of coronary atherosclerosis and acute coronary syndromes in patients with chronic kidney disease
.
Curr Probl Cardiol
.
2013
May
;
38
(
5
):
165
206
.
[PubMed]
0146-2806
13.
Mehran
R
,
Aymong
ED
,
Nikolsky
E
,
Lasic
Z
,
Iakovou
I
,
Fahy
M
, et al
A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: Development and initial validation. J Am Coll Cardiol.
2004
jen;44(7):1393–9.
14.
Alexander
JH
,
Reynolds
HR
,
Stebbins
AL
,
Dzavik
V
,
Harrington
RA
,
Van de Werf
F
, et al;
TRIUMPH Investigators
.
Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial
.
JAMA
.
2007
Apr
;
297
(
15
):
1657
66
.
[PubMed]
0098-7484
15.
Hamm
CW
,
Bassand
JP
,
Agewall
S
,
Bax
J
,
Boersma
E
,
Bueno
H
, et al;
ESC Committee for Practice Guidelines
.
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
.
Eur Heart J
.
2011
Dec
;
32
(
23
):
2999
3054
.
[PubMed]
0195-668X
16.
Ad-hoc working group of ERBP, Fliser D, Laville M, Covic A, Fouque D, Vanholder R, et al. A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc.
2012
Dec;27(12):4263–72.
17.
DeLong
ER
,
DeLong
DM
,
Clarke-Pearson
DL
.
Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach
.
Biometrics
.
1988
Sep
;
44
(
3
):
837
45
.
[PubMed]
0006-341X
18.
Ince
C
.
The central role of renal microcirculatory dysfunction in the pathogenesis of acute kidney injury
.
Nephron Clin Pract
.
2014
;
127
(
1-4
):
124
8
.
[PubMed]
1660-2110
19.
Akiyama
K
,
Kimura
A
,
Suzuki
H
,
Takeyama
Y
,
Gluckman
TL
,
Terhakopian
A
, et al
Production of oxidative products of nitric oxide in infarcted human heart
.
J Am Coll Cardiol
.
1998
Aug
;
32
(
2
):
373
9
.
[PubMed]
0735-1097
20.
Murr
C
,
Widner
B
,
Wirleitner
B
,
Fuchs
D
.
Neopterin as a marker for immune system activation
.
Curr Drug Metab
.
2002
Apr
;
3
(
2
):
175
87
.
[PubMed]
1389-2002
21.
Legrand
M
,
Almac
E
,
Mik
EG
,
Johannes
T
,
Kandil
A
,
Bezemer
R
, et al
L-NIL prevents renal microvascular hypoxia and increase of renal oxygen consumption after ischemia-reperfusion in rats
.
Am J Physiol Renal Physiol
.
2009
May
;
296
(
5
):
F1109
17
.
[PubMed]
1931-857X
22.
Wong
PC
,
Li
Z
,
Guo
J
,
Zhang
A
.
Pathophysiology of contrast-induced nephropathy
.
Int J Cardiol
.
2012
Jul
;
158
(
2
):
186
92
.
[PubMed]
0167-5273
23.
Kellum
JA
,
Lameire
N
;
KDIGO AKI Guideline Work Group
.
Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)
.
Crit Care
.
2013
Feb
;
17
(
1
):
204
.
[PubMed]
1364-8535
24.
Mehran
R
,
Dangas
GD
,
Weisbord
SD
. Contrast-Associated Acute Kidney Injury. N Engl J Med.
2019
30;380(22):2146–55.
25.
Yap
SC
,
Lee
HT
.
Acute kidney injury and extrarenal organ dysfunction: new concepts and experimental evidence
.
Anesthesiology
.
2012
May
;
116
(
5
):
1139
48
.
[PubMed]
0003-3022
26.
Siew
ED
,
Matheny
ME
.
Choice of Reference Serum Creatinine in Defining Acute Kidney Injury
.
Nephron
.
2015
;
131
(
2
):
107
12
.
[PubMed]
0028-2766
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.